Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels

被引:53
|
作者
Vollenweider, Franz X.
Barro, Martine
Csomor, Philipp A.
Feldon, Jorame
机构
[1] Univ Zurich, Hosp Psychiat, CH-8008 Zurich, Switzerland
[2] Swiss Fed Inst Technol, Lab Behav Neurobiol, Schwerzenbach, Switzerland
关键词
prepulse inhibition of acoustic startle; PPI; Cambridge Neuropsychological Test Automated Battery (CANTAB); antipsychotic; clozapine; normal volunteers; schizophrenia;
D O I
10.1016/j.biopsych.2006.03.058
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Atypical antipsychotics have been assessed for normalization effects on deficient sensory gating as indexed by prepulse inhibition (PPI) in schizophrenics with generally positive, although somewhat conflicting, results. Methods: We tested the acute effect of clozapine on startle, PPI, and attention, working memory, and executive functioning in 28 healthy male volunteers with low versus high PPI levels using a placebo-controlled within-subject design. Results: Clozapine significantly increased PPI levels obtained at short lead intervals of 60 and 120 msec in subjects with low PPI performance but showed no effect in subjects with high PPT Clozapine also caused a mild cognitive impairment on attention and pattern recognition memory tests. No correlations between cognitive measures and PPI performance were found. Moreover, low and high PPI performers were shown to exhibit stable levels of PPI across three separate nondrug testing days. Conclusions: Clozapine increases sensorimotor gating in healthy subjects with low but not high PPI levels in a manner comparable to that seen in dozapine-treated schizophrenia patients. Healthy subjects with low PPI level in combination with genetic studies may provide a translational model to elucidate the neuronal basis of PPI deficits and to test the efficacy of novel antipsychotic medication.
引用
收藏
页码:597 / 603
页数:7
相关论文
共 50 条
  • [21] Effects of smoking on acoustic startle and prepulse inhibition in humans
    Duncan, E
    Madonick, S
    Chakravorty, S
    Parwani, A
    Szilagyi, S
    Efferen, T
    Gonzenbach, S
    Angrist, B
    Rotrosen, J
    PSYCHOPHARMACOLOGY, 2001, 156 (2-3) : 266 - 272
  • [22] Effects of smoking on acoustic startle and prepulse inhibition in humans
    Erica Duncan
    Steven Madonick
    Subhajit Chakravorty
    Arti Parwani
    Sandor Szilagyi
    Toby Efferen
    Stephen Gonzenbach
    Burt Angrist
    John Rotrosen
    Psychopharmacology, 2001, 156 : 266 - 272
  • [23] MECHANISM OF PREPULSE INHIBITION
    GROVES, PM
    BOYLE, RD
    WELKER, RL
    MILLER, SW
    PHYSIOLOGY & BEHAVIOR, 1974, 12 (03) : 367 - 375
  • [24] Prepulse inhibition on the spot
    Valls-Sole, Josep
    CLINICAL NEUROPHYSIOLOGY, 2021, 132 (10) : 2679 - 2680
  • [25] PREPULSE INHIBITION IN SCHIZOPHRENICS, PARKINSON PATIENTS AND HEALTHY CONTROLS
    HAMM, A
    BAUER, U
    VAITL, D
    GALLHOFER, B
    JOURNAL OF PSYCHOPHYSIOLOGY, 1995, 9 (03) : 276 - 276
  • [26] Cortisol rapidly disrupts prepulse inhibition in healthy men
    Richter, Steffen
    Schulz, Andre
    Zech, Carina M.
    Oitzl, Melly S.
    Daskalakis, Nikolaos P.
    Blumenthal, Terry D.
    Schaechinger, Hartmut
    PSYCHONEUROENDOCRINOLOGY, 2011, 36 (01) : 109 - 114
  • [27] Discrepant findings of clozapine effects on prepulse inhibition of startle: Is it the route or the rat?
    Swerdlow, NR
    Varty, GB
    Geyer, MA
    NEUROPSYCHOPHARMACOLOGY, 1998, 18 (01) : 50 - 56
  • [28] Discrepant findings of clozapine effects on prepulse inhibition of startle: Is it the route or the rat?
    Swerdlow N.R.
    Varty G.B.
    Geyer M.A.
    Neuropsychopharmacology, 1998, 18 (1) : 50 - 56
  • [29] Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice
    Singer, Philipp
    Yee, Benjamin K.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 101 (01) : 107 - 114
  • [30] Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys
    Linn, GS
    Negi, SS
    Gerum, SV
    Javitt, DC
    PSYCHOPHARMACOLOGY, 2003, 169 (3-4) : 234 - 239